Pura Vida Investments’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-104,073
Closed -$5.28M 254
2022
Q1
$7.56M Buy
104,073
+50,144
+93% +$4.25M 0.25% 97
2021
Q4
$6.38M Buy
53,929
+11,870
+28% +$1.49M 0.23% 100
2021
Q3
$5.64M Sell
42,059
-172,841
-80% -$26.2M 0.17% 140
2021
Q2
$34.8M Buy
214,900
+24,900
+13% +$1.94M 1.08% 19
2021
Q1
$15.2M Buy
+190,000
New +$12.8M 0.43% 48

Other funds holding NTLA

Pura Vida Investments's NTLA Position: Q2 2022 in Review

Pura Vida Investments sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 104,073 shares — an estimated $5.28M sold.

Pura Vida Investments first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $34.8M in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Pura Vida Investments reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pura Vida Investments sold 104,073 Intellia Therapeutics shares in Q2 2022, an estimated $5.28M.
  • Pura Vida Investments first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
  • Pura Vida Investments's Intellia Therapeutics position peaked at $34.8M in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.